Targeting Gα₁₃-integrin interaction ameliorates systemic inflammation

Area of Science:

• Biomedical Science
• Immunology
• Hematology

Background:

• Sepsis involves excessive inflammation and thrombosis, a thrombo-inflammatory state inadequately treated by current drugs.
• Current therapies fail to address the dual nature of inflammation and thrombosis in sepsis, often leading to vascular leakage or hemorrhage.

Purpose of the Study:

• To investigate the efficacy of MB2mP6 peptide nanoparticles in treating systemic inflammation and thrombosis in sepsis.
• To explore the role of Gα13 signaling in leukocytes and platelets during sepsis-induced thrombo-inflammation.

Main Methods:

• Utilized MB2mP6 peptide nanoparticles targeting Gα13-mediated integrin signaling in a mouse model of severe sepsis.
• Assessed the impact of MB2mP6 on inflammation, thrombosis, vascular leakage, and survival.
• Employed Gα13 knockout mice (platelet-specific, leukocyte-specific, and dual) to elucidate the roles of Gα13 in different cell types.

Main Results:

• MB2mP6 nanoparticles inhibited both sepsis-induced inflammation and thrombosis without causing hemorrhage.
• MB2mP6 treatment significantly improved survival in mice with severe sepsis.
• Genetic ablation of Gα13 in platelets or leukocytes partially improved survival, while dual knockout mimicked the therapeutic effect of MB2mP6.

Conclusions:

• Systemic inflammation and thrombosis independently contribute to sepsis mortality and exacerbate each other.
• Targeting Gα13 signaling offers a novel therapeutic strategy for dual anti-inflammatory and anti-thrombotic action in sepsis.
• MB2mP6 represents a promising therapeutic concept for sepsis, providing combined benefits without adverse vascular effects.